Voyager Therapeutics, Inc. (VYGR) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
34/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseVYGR / S&P -9.33% / 15.20% |
LoseVYGR / S&P -19.07% / 15.00% |
LoseVYGR / S&P -2.69% / 50.40% |
| 2026-Q12/3 |
WinVYGR / S&P -1.78% / -4.33% |
LoseVYGR / S&P -45.50% / 11.30% |
WinVYGR / S&P 34.69% / 27.70% |
| 2025-Q41/3 |
LoseVYGR / S&P -15.85% / 2.65% |
LoseVYGR / S&P -49.53% / 9.00% |
WinVYGR / S&P 78.95% / 13.40% |
| 2025-Q31/3 |
WinVYGR / S&P 50.16% / 8.12% |
LoseVYGR / S&P -80.88% / 4.61% |
LoseVYGR / S&P -433.85% / 13.45% |
| 2025-Q20/3 |
LoseVYGR / S&P -7.99% / 10.94% |
LoseVYGR / S&P -70.38% / 4.83% |
LoseVYGR / S&P -945.45% / 10.63% |
| 2025-Q11/3 |
LoseVYGR / S&P -40.39% / -4.27% |
LoseVYGR / S&P -43.75% / 4.98% |
WinVYGR / S&P 1236.36% / 10.57% |
| 2024-Q40/3 |
LoseVYGR / S&P -3.08% / 2.41% |
LoseVYGR / S&P -68.00% / 5.25% |
LoseVYGR / S&P -137.62% / 6.15% |
| 2024-Q30/3 |
LoseVYGR / S&P -26.04% / 5.89% |
LoseVYGR / S&P 3.40% / 5.89% |
LoseVYGR / S&P -46.72% / 6.11% |
| 2024-Q20/3 |
LoseVYGR / S&P -15.04% / 4.28% |
LoseVYGR / S&P -26.22% / 5.38% |
LoseVYGR / S&P -90.27% / 5.12% |
| 2024-Q10/3 |
LoseVYGR / S&P 10.31% / 10.56% |
LoseVYGR / S&P -37.58% / 5.71% |
LoseVYGR / S&P -104.85% / 5.59% |
| 2023-Q41/3 |
LoseVYGR / S&P 8.90% / 11.69% |
WinVYGR / S&P 511.18% / 6.81% |
LoseVYGR / S&P -346.34% / 7.78% |
| 2023-Q31/3 |
LoseVYGR / S&P -32.31% / -3.27% |
WinVYGR / S&P 124.58% / 7.52% |
LoseVYGR / S&P -365.22% / -5.03% |
| 2023-Q22/3 |
WinVYGR / S&P 48.51% / 8.74% |
WinVYGR / S&P 530.13% / 9.50% |
LoseVYGR / S&P -243.04% / -8.57% |
| 2023-Q12/3 |
WinVYGR / S&P 26.39% / 7.50% |
WinVYGR / S&P 504.14% / 10.77% |
LoseVYGR / S&P -220.74% / -15.69% |
| 2022-Q40/3 |
LoseVYGR / S&P 3.04% / 7.56% |
LoseVYGR / S&P 9.34% / 11.88% |
LoseVYGR / S&P -35.26% / -17.99% |
| 2022-Q32/3 |
WinVYGR / S&P 0.17% / -4.88% |
WinVYGR / S&P 344.22% / 13.47% |
LoseVYGR / S&P -81.38% / -1.41% |
| 2022-Q20/3 |
LoseVYGR / S&P -22.44% / -16.10% |
LoseVYGR / S&P -76.61% / 13.71% |
LoseVYGR / S&P -436.17% / 11.04% |
| 2022-Q11/3 |
WinVYGR / S&P 181.18% / -4.60% |
LoseVYGR / S&P -80.21% / 15.97% |
LoseVYGR / S&P -280.77% / 42.23% |
| 2021-Q40/3 |
LoseVYGR / S&P 3.04% / 11.03% |
LoseVYGR / S&P -78.14% / 15.00% |
LoseVYGR / S&P VYGR unavailable / 96.40% |
| 2021-Q30/3 |
LoseVYGR / S&P -36.32% / 0.58% |
LoseVYGR / S&P -91.95% / 10.77% |
LoseVYGR / S&P VYGR unavailable / 69.42% |
| 2021-Q21/3 |
LoseVYGR / S&P -12.31% / 8.55% |
WinVYGR / S&P 32.43% / 6.58% |
LoseVYGR / S&P VYGR unavailable / 51.81% |
| 2021-Q11/3 |
LoseVYGR / S&P -34.13% / 6.17% |
WinVYGR / S&P 36.07% / -1.06% |
LoseVYGR / S&P VYGR unavailable / 7.39% |
| 2020-Q41/3 |
LoseVYGR / S&P -32.99% / 12.15% |
WinVYGR / S&P 63.93% / -3.72% |
LoseVYGR / S&P VYGR unavailable / -33.42% |
| 2020-Q31/3 |
LoseVYGR / S&P -15.45% / 8.93% |
WinVYGR / S&P 167.57% / -2.04% |
LoseVYGR / S&P VYGR unavailable / -27.10% |
| 2020-Q22/3 |
WinVYGR / S&P 37.92% / 20.54% |
WinVYGR / S&P 80.29% / -0.46% |
LoseVYGR / S&P VYGR unavailable / -27.11% |
| 2020-Q11/3 |
LoseVYGR / S&P -34.41% / -19.60% |
WinVYGR / S&P 887.54% / 3.47% |
LoseVYGR / S&P VYGR unavailable / -14.75% |
| 2019-Q41/3 |
LoseVYGR / S&P -18.94% / 9.07% |
WinVYGR / S&P 1270.14% / 5.36% |
LoseVYGR / S&P VYGR unavailable / 2.99% |
| 2019-Q31/3 |
LoseVYGR / S&P -36.77% / 1.70% |
WinVYGR / S&P 516.64% / 5.02% |
LoseVYGR / S&P VYGR unavailable / 0.21% |
| 2019-Q22/3 |
WinVYGR / S&P 42.22% / 4.30% |
WinVYGR / S&P 403.05% / 6.64% |
LoseVYGR / S&P VYGR unavailable / 8.65% |
| 2019-Q12/3 |
WinVYGR / S&P 103.62% / 13.65% |
WinVYGR / S&P 23.53% / 8.12% |
LoseVYGR / S&P VYGR unavailable / 14.29% |
| 2018-Q40/3 |
LoseVYGR / S&P -50.32% / -13.52% |
LoseVYGR / S&P -24.82% / 9.05% |
LoseVYGR / S&P VYGR unavailable / 18.23% |
| 2018-Q31/3 |
LoseVYGR / S&P -3.17% / 7.71% |
WinVYGR / S&P 94.37% / 10.21% |
LoseVYGR / S&P VYGR unavailable / 19.06% |
| 2018-Q22/3 |
WinVYGR / S&P 3.99% / 3.43% |
WinVYGR / S&P 32.48% / 9.03% |
LoseVYGR / S&P VYGR unavailable / 14.46% |
| 2018-Q11/3 |
WinVYGR / S&P 13.19% / -0.76% |
LoseVYGR / S&P -11.44% / 7.68% |
LoseVYGR / S&P VYGR unavailable / 12.46% |
| 2017-Q40/3 |
LoseVYGR / S&P -19.38% / 6.64% |
LoseVYGR / S&P -28.73% / 7.03% |
LoseVYGR / S&P VYGR unavailable / 13.82% |
| 2017-Q31/3 |
WinVYGR / S&P 129.80% / 4.48% |
LoseVYGR / S&P -63.38% / 5.68% |
LoseVYGR / S&P VYGR unavailable / 17.57% |
| 2017-Q20/3 |
LoseVYGR / S&P -32.33% / 3.09% |
LoseVYGR / S&P -54.89% / 4.83% |
LoseVYGR / S&P VYGR unavailable / 17.74% |
| 2017-Q10/3 |
LoseVYGR / S&P 3.92% / 6.07% |
LoseVYGR / S&P -44.59% / 3.67% |
LoseVYGR / S&P VYGR unavailable / 13.32% |
| 2016-Q41/3 |
WinVYGR / S&P 6.08% / 3.82% |
LoseVYGR / S&P -17.96% / 2.09% |
LoseVYGR / S&P VYGR unavailable / 7.05% |
| 2016-Q31/3 |
WinVYGR / S&P 9.28% / 3.85% |
LoseVYGR / S&P VYGR unavailable / 0.20% |
LoseVYGR / S&P VYGR unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | VYGR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 2.98% | 20.78% |
| Annualized return | 2.98% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | VYGR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 0.29% | 83.14% |
| Annualized return | 0.06% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | VYGR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -71.71% | 319.30% |
| Annualized return | -11.86% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |